Co-Diagnostics (CODX) EBIAT (2017 - 2025)
Historic EBIAT for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.
- Co-Diagnostics' EBIAT rose 3928.89% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year increase of 2204.92%. This contributed to the annual value of -$37.6 million for FY2024, which is 652.69% down from last year.
- As of Q3 2025, Co-Diagnostics' EBIAT stood at -$5.9 million, which was up 3928.89% from -$7.7 million recorded in Q2 2025.
- In the past 5 years, Co-Diagnostics' EBIAT ranged from a high of $11.7 million in Q1 2022 and a low of -$21.9 million during Q4 2022
- Over the past 5 years, Co-Diagnostics' median EBIAT value was -$6.0 million (recorded in 2023), while the average stood at -$3.8 million.
- As far as peak fluctuations go, Co-Diagnostics' EBIAT soared by 84155.34% in 2021, and later tumbled by 39213.5% in 2022.
- Over the past 5 years, Co-Diagnostics' EBIAT (Quarter) stood at $7.5 million in 2021, then crashed by 392.13% to -$21.9 million in 2022, then skyrocketed by 33.0% to -$14.7 million in 2023, then increased by 24.84% to -$11.0 million in 2024, then soared by 46.63% to -$5.9 million in 2025.
- Its EBIAT stands at -$5.9 million for Q3 2025, versus -$7.7 million for Q2 2025 and -$7.5 million for Q1 2025.